3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
21
Phase 2
3
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
5
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Glioma
1
Epidural Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Alzheimer Disease
1
Interventions
Oncolytic Virotherapy
2
tucatinib
1
trifluridine tipiracil drug combination
1
tribenoside (combination)
1
tribenoside
1
trastuzumab deruxtecan
1
tipiracil
1
sotorasib
1
sintilimab
1
semaglutide
1
regorafenib
1
polyethylene glycol 400
1
penpulimab
1
palbociclib
1
montelukast
1
encorafenib
1
binimetinib
1
balstilimab
1
adagrasib
1
Trifluridine
1
Tobacco Use Cessation Devices
1
Tablets
1
Suppositories
1
Standard of Care
1
Specimen Handling
1
Receptor Protein-Tyrosine Kinases
1
Radiosurgery
1
Polyethylene Glycols
1
Pentoxifylline
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Colorectal Neoplasms
×
Blood Specimen Collection
×
Clear all
NCT01329718
2014-08-04
SPR0012
Epigenomics, Inc
Phase EARLY_PHASE1
Completed
562 enrolled